Extract

• To understand the impact of ocrelizumab treatment on neurofilament light (NfL) as a biomarker of neuronal damage in cerebrospinal fluid (CSF) • To assess the number of cluster of differentiation (CD)19+ B cells in CSF (cell number/microliter) before and after treatment with ocrelizumab • To assess the number of CD3+ T cells in CSF (cell number/microliter) before and after treatment with ocrelizumab

Inclusion criteria

• Relapsing Multiple Sclerosis